GnRH antagonists in the treatment of advanced prostate cancer

Canadian Journal of Urology

Volumn 17, Issue 2, 2010, Pages 5063-5070

  Pommerville, Peter J ^a   De Boer, Johan G ^b  

^a Can Med Clinical Research Inc   (Canada)

^b De Boer Consulting   (Canada)

Author keywords

GnRH antagonists; Prostate cancer; Testosterone; Treatment modality

Indexed keywords

GONADORELIN; HORMONE ANTAGONIST;

CLINICAL TRIAL; DOSE RESPONSE; DRUG ANTAGONISM; HUMAN; MALE; PROSTATE TUMOR; REVIEW; TREATMENT OUTCOME;

CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; GONADOTROPIN-RELEASING HORMONE; HORMONE ANTAGONISTS; HUMANS; MALE; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 77956213440     PISSN: 11959479     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Canadian Cancer Society. Canadian Cancer Statistics 2009. ISSN 0835-2976. 2009. Toronto.
2. Huggins C, Hodges CV. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941;1:293-297.
3. Seidenfeld J, Samson DJ, Hasselblad V, Aronson N, Albertsen PC, Bennett CL, Wilt TJ. Single-therapy androgen suppression in men with advanced prostate cancer: A systematic review and meta-analysis. Ann Intern Med 2000;132(7):566-577.
4. Takase M, Tsutsui K, Kawashima S. Effects of PRL and FSH on LH binding and number of Leydig cells in hypophysectomized mice. Endocrinol Jpn 1990;37(2):193-203.
5. Gnanapragasam VJ, Robson CN, Neal DE, Leung HY. Regulation of FGF8 expression by the androgen receptor in human prostate cancer. Oncogene 2002;21(33):5069-5080. 6. Ben Josef E, Yang SY, Ji TH, Bidart JM, Garde SV, Chopra DP, Porter AT, Tang DG. Hormone-refractory prostate cancer cells express functional follicle-stimulating hormone receptor (FSHR). J Urol 1999;161(3):970-976.
6. Ben Josef E, Yang SY, Ji TH, Bidart JM, Garde SV, Chopra DP, Porter AT, Tang DG. Hormone-refractory prostate cancer cells express functional follicle-stimulating hormone receptor (FSHR). J Urol 1999;161(3):970-976
7. Mariani S, Salvatori L, Basciani S, Arizzi M, Franco G, Petrangeli E, Spera G, Gnessi L. Expression and cellular localization of follicle-stimulating hormone receptor in normal human prostate, benign prostatic hyperplasia and prostate cancer. J Urol 2006;175(6):2072-2077.
8. Simoni M, Weinbauer GF, Chandolia RK, Nieschlag E. Microheterogeneity of pituitary follicle-stimulating hormone in male rats:differential effects of the chronic androgen deprivation induced by castration or androgen blockade. J Mol Endocrinol 1992;9(2):175-182.
9. Kakar SS, Jennes L. Expression of gonadotropin-releasing hormone and gonadotropin-releasing hormone receptor mRNAs in various non-reproductive human tissues. Cancer Lett 1995;98(1):57-62.
10. Wormald PJ, Eidne KA, Millar RP. Gonadotropin-releasing hormone receptors in human pituitary:ligand structural requirements, molecular size, and cationic effects. J Clin Endocrinol Metab 1985;61(6):1190-1194.
11. Bubley GJ. Is the flare phenomenon clinically significant? Urology 2001;58(2 Suppl 1):5-9.
12. Mahler C. Is disease flare a problem? Cancer 1993;72(12 Suppl):3799-3802.
13. McLeod D, Zinner N, Tomera K, Gleason D, Fotheringham N, Campion M, Garnick MB. A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer. Urology 2001;58(5):756-761.
14. Morote J, Esquena S, Abascal JM, Trilla E, Cecchini L, Raventos CX, Catalan R, Reventos J. Failure to maintain a suppressed level of serum testosterone during long-acting depot luteinizing hormone-releasing hormone agonist therapy in patients with advanced prostate cancer. Urol Int 2006;77(2):135-138.
15. Fontana D, Mari M, Martinelli A, Boccafoschi C, Magno C, Turriziani M, Maymone SS, Cunico SC, Zanollo A, Montagna G, Frongia M, Jacobellis U. 3-month formulation of goserelin acetate ('Zoladex' 10.8-mg depot) in advanced prostate cancer:results from an Italian, open, multicenter trial. Urol Int 2003;70(4):316-320.
16. Tombal B. Appropriate castration with luteinising hormone releasing hormone (LHRH) agonists:what is the optimal level of testosterone? Eur Urol Suppl 2005;4:14-19.
17. Oefelein MG, Cornum R. Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy:the case for monitoring serum testosterone and a treatment decision algorithm. J Urol 2000;164(3 Pt 1):726-729.
18. Fluker MR. Gonadotropin-releasing hormone antagonists. Curr Opin Endocrinol and Diabetes 2000;7(6):350-356.
19. Horvath JE, Bajo AM, Schally AV, Kovacs M, Herbert F, Groot K. Effects of long-term treatment with the luteinizing hormonereleasing hormone (LHRH) agonist Decapeptyl and the LHRH antagonist Cetrorelix on the levels of pituitary LHRH receptors and their mRNA expression in rats. Proc Natl Acad Sci USA 2002;99(23):15048-15053.
20. Kovacs M, Schally AV. Comparison of mechanisms of action of luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix and LHRH agonist triptorelin on the gene expression of pituitary LHRH receptors in rats. Proc Natl Acad Sci USA 2001;98(21):12197-12202.
21. Kovacs M, Schally AV, Csernus B, Rekasi Z. Luteinizing hormone-releasing hormone (LH-RH) antagonist Cetrorelix down-regulates the mRNA expression of pituitary receptors for LH-RH by counteracting the stimulatory effect of endogenous LH-RH. Proc Natl Acad Sci USA 2001;98(4):1829-1834.
22. Gonzalez-Barcena D, Vadillo-Buenfil M, Gomez-Orta F, Fuentes GM, Cardenas-Cornejo I, Graef-Sanchez A, Comaru-Schally AM, Schally AV. Responses to the antagonistic analog of LH-RH (SB-75, Cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer. Prostate 1994;24(2):84-92.
23. Gonzalez-Barcena D, Vadillo-Buenfil M, Cortez-Morales A, Fuentes-Garcia M, Cardenas-Cornejo I, Comaru-Schally AM, Schally AV. Luteinizing hormone-releasing hormone antagonist cetrorelix as primary single therapy in patients with advanced prostatic cancer and paraplegia due to metastatic invasion of spinal cord. Urology 1995;45(2):275-281.
24. Gonzalez-Barcena D, Schally AV, Comaru-Schally AM. Treatment of patients with advanced prostate cancer with LHRH antagonist Cetrorelix. In Treatment with LHRH analogs:Controversies and Perspectives (Filicori, M. and Flamigni, C., eds). 1996 pp. 139-145, Parthenon Publishing group, London, New York.
25. Beer TM, Ryan C, Bhat G, Garnick M. Dose-escalated abarelix in androgen-independent prostate cancer:a phase I study. Anticancer Drugs 2006;17(9):1075-1079.
26. Koch M, Steidle C, Brosman S, Centeno A, Gaylis F, Campion M, Garnick MB. An open-label study of abarelix in men with symptomatic prostate cancer at risk of treatment with LHRH agonists. Urology 2003;62(5):877-882.
27. Trachtenberg J, Gittleman M, Steidle C, Barzell W, Friedel W, Pessis D, Fotheringham N, Campion M, Garnick MB. A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. J Urol 2002;167(4):1670-1674.
28. Tomera K, Gleason D, Gittelman M, Moseley W, Zinner N, Murdoch M, Menon M, Campion M, Garnick MB. The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin:initial results of endocrinological and biochemical efficacies in patients with prostate cancer. J Urol 2001;165(5):1585-1589.
29. Garnick MB, Campion M. Abarelix Depot, a GnRH antagonist, v LHRH superagonists in prostate cancer:differential effects on follicle-stimulating hormone. Abarelix Depot study group. Mol Urol 2000;4(3):275-277.
30. Beer TM, Garzotto M, Eilers KM, Lemmon D. Phase II study of abarelix depot for androgen independent prostate cancer progression during gonadotropin-releasing hormone agonist therapy. J Urol 2003;169(5):1738-1741.
31. Jiang G, Stalewski J, Galyean R, Dykert J, Schteingart C, Broqua P, Aebi A, Aubert ML, Semple G, Robson P, Akinsanya K, Haigh R, Riviere P, Trojnar J, Junien JL, Rivier JE. GnRH antagonists:a new generation of long acting analogues incorporating pureido- phenylalanines at positions 5 and 6. J Med Chem 2001;44(3):453-467.
32. Broqua P, Riviere PJ, Conn PM, Rivier JE, Aubert ML, Junien JL. Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist:degarelix. J Pharmacol Exp Ther 2002;301(1):95-102.
33. Gittelman M, Pommerville PJ, Persson BE, Jensen JK, Olesen TK. A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America. J Urol 2008;180(5):1986-1992.
34. Van Poppel H, Tombal B, de la Rosette JJ, Persson BE, Jensen JK, Kold OT. Degarelix:a novel gonadotropin-releasing hormone (GnRH) receptor blocker--results from a 1-yr, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancer. Eur Urol 2008;54(4):805-813.
35. Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P, Jensen JK, Olesen TK, Schroder FH. The efficacy and safety of degarelix:a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int 2008;102(11):1531-1538.
36. Tombal B, Miller K, Boccon-Gibod L, Schroder FH, Jensen JK, Olesen TK, Person B-E. Degarelix vs. Leuprolide treatment in patients with advanced prostate cancer:PSA failures during a randomised, phase III trial (CS21). Eur Urol Suppl 2009;8(4):130 (abstract).
37. Higano CS. Side effects of androgen deprivation therapy:monitoring and minimizing toxicity. Urology 2003;61(2 Suppl 1):32-38.
38. Smith MR. Changes in fat and lean body mass during androgendeprivation therapy for prostate cancer. Urology 2004;63(4):742-745.
39. Rivier JE, Porter J, Rivier CL, Perrin M, Corrigan A, Hook WA, Siraganian RP, Vale WW. New effective gonadotropin releasing hormone antagonists with minimal potency for histamine release in vitro. J Med Chem 1986;29(10):1846-1851.
40. Rosenblatt DE, Mellow A. Depression during hormonal treatment of prostate cancer. J Am Board Fam Pract 1995;8(4):317-320.
41. Green HJ, Pakenham KI, Headley BC, Yaxley J, Nicol DL, Mactaggart PN, Swanson C, Watson RB, Gardiner RA. Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate:a randomized controlled trial. BJU Int 2002;90(4):427-432.
42. Jim HS, Small BJ, Patterson S, Salup R, Jacobsen PB. Cognitive impairment in men treated with luteinizing hormone-releasing hormone agonists for prostate cancer:a controlled comparison. Support Care Cancer 2009 Apr 3.
43. Craig MC, Fletcher PC, Daly EM, Rymer J, Brammer M, Giampietro V, Stahl D, Maki PM, Murphy DG. The interactive effect of the cholinergic system and acute ovarian suppression on the brain:an fMRI study. Horm Behav 2009;55(1):41-49.
44. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of the "androgen deprivation syndrome" in men receiving androgen deprivation for prostate cancer. Arch Intern Med 2006;166(4):465-471.
45. Nishiyama T, Kanazawa S, Watanabe R, Terunuma M, Takahashi K. Influence of hot flashes on quality of life in patients with prostate cancer treated with androgen deprivation therapy. Int J Urol 2004;11(9):735-741.
46. Vilar GS, Montana PF, Aguayo MM, Villas Sanchez MV, Sevillano Capellan MM, Sabater M. S. [Review of current treatment for hot flushes induced by androgen deprivation in prostate carcinoma]. Actas Urol Esp 2009;33(4):337-343.
47. Daniell HW. Osteoporosis due to androgen deprivation therapy in men with prostate cancer. Urology 2001;58(2 Suppl 1):101-107.
48. Eastham JA. Bone health in men receiving androgen deprivation therapy for prostate cancer. J Urol 2007;177(1):17-24. 49. Israeli RS, Ryan CW, Jung LL. Managing bone loss in men with locally advanced prostate cancer receiving androgen deprivation therapy. J Urol 2008;179(2):414-423.
49. Israeli RS, Ryan CW, Jung LL. Managing bone loss in men with locally advanced prostate cancer receiving androgen deprivation therapy. J Urol 2008;179(2):414-423.
50. Greenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL, Resnick NM. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab 2005;90(12):6410-6417.
51. Sun L, Peng Y, Sharrow AC, Iqbal J, Zhang Z, Papachristou DJ, Zaidi S, Zhu LL, Yaroslavskiy BB, Zhou H, Zallone A, Sairam MR, Kumar TR, Bo W, Braun J, Cardoso-Landa L, Schaffler MB, Moonga BS, Blair HC, Zaidi M. FSH directly regulates bone mass. Cell 2006;125(2):247-260.
52. Kawai H, Furuhashi M, Suganuma N. Serum follicle-stimulating hormone level is a predictor of bone mineral density in patients with hormone replacement therapy. Arch Gynecol Obstet 2004;269(3):192-195.
53. Comaru-Schally AM, Brannan W, Schally AV, Colcolough M, Monga M. Efficacy and safety of luteinizing hormone-releasing hormone antagonist cetrorelix in the treatment of symptomatic benign prostatic hyperplasia. J Clin Endocrinol Metab 1998;83(11):3826-3831.
54. Debruyne F, Gres AA, Arustamov DL. Placebo-controlled dose-ranging phase 2 study of subcutaneously administered LHRH antagonist cetrorelix in patients with symptomatic benign prostatic hyperplasia. Eur Urol 2008;54(1):170-177.
55. Pinski J, Reile H, Halmos G, Groot K, Schally AV. Inhibitory effects of analogs of luteinizing hormone-releasing hormone on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer. Int J Cancer 1994;59(1):51-55.
56. Princivalle M, Broqua P, White R, Meyer J, Mayer G, Elliott L, Bjarnason K, Haigh R, Yea C. Rapid suppression of plasma testosterone levels and tumor growth in the dunning rat model treated with degarelix, a new gonadotropin-releasing hormone antagonist. J Pharmacol Exp Ther 2007;320(3):1113-1118.